Skip to main content
. 2017 Nov 24;15(2):1580–1590. doi: 10.3892/ol.2017.7484

Figure 5.

Figure 5.

Percentage of CLL iNKT cells with (A) IL-4 or (B) IFN-γ expression in patients with CLL at various disease stages (three risk groups), as compared with in HVs. (C) Inter-group comparisons of the iNKT+IFN-γ+: iNKT+IL-4+ ratio among different risk groups of patients with CLL, and HVs. CLL, chronic lymphocytic leukemia; iNKT, invariant natural killer T cells; IL, interleukin; IFN, interferon; HV, healthy volunteer.